Literature DB >> 19065127

Zoledronic acid ameliorates the effects of endocrine therapy on bone health in women with early-stage breast cancer.

Robert E Coleman1.   

Abstract

Entities:  

Year:  2008        PMID： 19065127     DOI： 10.1038/ncpendmet1045

Source DB:  PubMed          Journal:  Nat Clin Pract Endocrinol Metab        ISSN： 1745-8366


× No keyword cloud information.
  7 in total

1.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

2.  Practical guidance for the management of aromatase inhibitor-associated bone loss.

Authors:  P Hadji; J-J Body; M S Aapro; A Brufsky; R E Coleman; T Guise; A Lipton; M Tubiana-Hulin
Journal:  Ann Oncol       Date:  2008-04-29       Impact factor: 32.976

Review 3.  Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies.

Authors:  Robert E Coleman; Jean-Jacques Body; Julie R Gralow; Allan Lipton
Journal:  Cancer Treat Rev       Date:  2008-05-16       Impact factor: 12.111

4.  Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.

Authors:  David M Reid; Julie Doughty; Richard Eastell; Steven D Heys; Anthony Howell; Eugene V McCloskey; Trevor Powles; Peter Selby; Robert E Coleman
Journal:  Cancer Treat Rev       Date:  2008-06-02       Impact factor: 12.111

5.  Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.

Authors:  Michael Gnant; Brigitte Mlineritsch; Gero Luschin-Ebengreuth; Franz Kainberger; Helmut Kässmann; Jutta Claudia Piswanger-Sölkner; Michael Seifert; Ferdinand Ploner; Christian Menzel; Peter Dubsky; Florian Fitzal; Vesna Bjelic-Radisic; Günther Steger; Richard Greil; Christian Marth; Ernst Kubista; Hellmut Samonigg; Peter Wohlmuth; Martina Mittlböck; Raimund Jakesz
Journal:  Lancet Oncol       Date:  2008-08-19       Impact factor: 41.316

6.  Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.

Authors:  Richard Eastell; Judith E Adams; Robert E Coleman; Anthony Howell; Rosemary A Hannon; Jack Cuzick; John R Mackey; Matthias W Beckmann; Glen Clack
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544

Review 7.  American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

Authors:  Eric P Winer; Clifford Hudis; Harold J Burstein; Antonio C Wolff; Kathleen I Pritchard; James N Ingle; Rowan T Chlebowski; Richard Gelber; Stephan B Edge; Julie Gralow; Melody A Cobleigh; Eleftherios P Mamounas; Lori J Goldstein; Timothy J Whelan; Trevor J Powles; John Bryant; Cheryl Perkins; Judy Perotti; Susan Braun; Amy S Langer; George P Browman; Mark R Somerfield
Journal:  J Clin Oncol       Date:  2004-11-15       Impact factor: 44.544
  7 in total
  1 in total

1.  Bisphosphonate use after estrogen receptor-positive breast cancer and risk of contralateral breast cancer.

Authors:  Genevieve M Monsees; Kathleen E Malone; Mei-Tzu C Tang; Polly A Newcomb; Christopher I Li
Journal:  J Natl Cancer Inst       Date:  2011-10-21       Impact factor: 13.506
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.